BACKGROUND: Optimal empiric therapy for hospitalized patients with healthcare-associated pneumonia (HCAP) is uncertain. METHODS: We prospectively applied a therapeutic algorithm, based on the presence of risk factors for multidrug-resistant (MDR) pathogens in a multicenter cohort study of 445 pneumonia patients, including both community-acquired pneumonia (CAP; n = 124) and HCAP (n = 321). RESULTS: MDR pathogens were more common (15.3% vs 0.8%, P < .001) in HCAP patients than in CAP patients, including Staphylococcus aureus (11.5% vs 0.8%, P < .001); methicillin-resistant S. aureus (6.9% vs 0%, P = .003); Enterobacteriaceae (7.8% vs 2.4%, P = .037); and Pseudomonas aeruginosa (6.9% vs 0.8%, P = .01). Using the proposed algorithm, HCAP patients with ≥2 MDR risk factors, one of which was severity of illness (n = 170), vs HCAP patients with 0-1 risk factor (n = 151) had a significantly higher frequency of MDR pathogens (27.1% vs 2%, P < .001). In total, 93.1% of HCAP patients were treated according to the therapy algorithm, with only 53% receiving broad-spectrum empiric therapy, yet 92.9% received appropriate therapy for the identified pathogen. Thirty-day mortality was significantly higher for HCAP than for CAP (13.7% vs 5.6%, P = .017), but among HCAP patients with 0-1 MDR risk factor, mortality was lower than with ≥2 MDR risk factors (8.6% vs 18.2%, P = .012). In multivariate analysis, initial treatment failure, but not inappropriate empiric antibiotic therapy, was a mortality risk factor (odds ratio, 72.0). CONCLUSIONS: Basing empiric HCAP therapy on its severity and the presence of risk factors for MDR pathogens is a potentially useful approach that achieves good outcomes without excessive use of broad-spectrum antibiotic therapy. CLINICAL TRIALS REGISTRATION: Japan Medical Association Center for Clinical Trials, JMA-IIA00054.
BACKGROUND: Optimal empiric therapy for hospitalized patients with healthcare-associated pneumonia (HCAP) is uncertain. METHODS: We prospectively applied a therapeutic algorithm, based on the presence of risk factors for multidrug-resistant (MDR) pathogens in a multicenter cohort study of 445 pneumoniapatients, including both community-acquired pneumonia (CAP; n = 124) and HCAP (n = 321). RESULTS: MDR pathogens were more common (15.3% vs 0.8%, P < .001) in HCAPpatients than in CAPpatients, including Staphylococcus aureus (11.5% vs 0.8%, P < .001); methicillin-resistant S. aureus (6.9% vs 0%, P = .003); Enterobacteriaceae (7.8% vs 2.4%, P = .037); and Pseudomonas aeruginosa (6.9% vs 0.8%, P = .01). Using the proposed algorithm, HCAPpatients with ≥2 MDR risk factors, one of which was severity of illness (n = 170), vs HCAPpatients with 0-1 risk factor (n = 151) had a significantly higher frequency of MDR pathogens (27.1% vs 2%, P < .001). In total, 93.1% of HCAPpatients were treated according to the therapy algorithm, with only 53% receiving broad-spectrum empiric therapy, yet 92.9% received appropriate therapy for the identified pathogen. Thirty-day mortality was significantly higher for HCAP than for CAP (13.7% vs 5.6%, P = .017), but among HCAPpatients with 0-1 MDR risk factor, mortality was lower than with ≥2 MDR risk factors (8.6% vs 18.2%, P = .012). In multivariate analysis, initial treatment failure, but not inappropriate empiric antibiotic therapy, was a mortality risk factor (odds ratio, 72.0). CONCLUSIONS: Basing empiric HCAP therapy on its severity and the presence of risk factors for MDR pathogens is a potentially useful approach that achieves good outcomes without excessive use of broad-spectrum antibiotic therapy. CLINICAL TRIALS REGISTRATION: Japan Medical Association Center for Clinical Trials, JMA-IIA00054.
Authors: Sara Tomczyk; Seema Jain; Anna M Bramley; Wesley H Self; Evan J Anderson; Chris Trabue; D Mark Courtney; Carlos G Grijalva; Grant W Waterer; Kathryn M Edwards; Richard G Wunderink; Lauri A Hicks Journal: Open Forum Infect Dis Date: 2017-06-20 Impact factor: 3.835
Authors: Wesley H Self; Richard G Wunderink; Derek J Williams; Tyler W Barrett; Adrienne H Baughman; Carlos G Grijalva Journal: Acad Emerg Med Date: 2015-05-20 Impact factor: 3.451
Authors: Russell T Attridge; Christopher R Frei; Mary Jo V Pugh; Kenneth A Lawson; Laurajo Ryan; Antonio Anzueto; Mark L Metersky; Marcos I Restrepo; Eric M Mortensen Journal: J Crit Care Date: 2016-08-11 Impact factor: 3.425
Authors: Christopher R Frei; Sylvie Rehani; Grace C Lee; Natalie K Boyd; Erene Attia; Ashley Pechal; Rachel S Britt; Eric M Mortensen Journal: Pharmacotherapy Date: 2017-02-03 Impact factor: 4.705
Authors: P Garcinuño; M Santibañez; L Gimeno; A Sánchez-Bautista; J Coy; J Sánchez-Paya; V Boix; E Merino; J Portilla; J C Rodríguez Journal: Eur J Clin Microbiol Infect Dis Date: 2016-08-09 Impact factor: 3.267
Authors: Michael B Rothberg; Sarah Haessler; Tara Lagu; Peter K Lindenauer; Penelope S Pekow; Aruna Priya; Daniel Skiest; Marya D Zilberberg Journal: Infect Control Hosp Epidemiol Date: 2014-10 Impact factor: 3.254